Calamos Advisors LLC Cuts Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Calamos Advisors LLC lessened its holdings in CareDx, Inc (NASDAQ:CDNA - Free Report) by 29.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 87,265 shares of the company's stock after selling 36,137 shares during the period. Calamos Advisors LLC owned approximately 0.16% of CareDx worth $1,868,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quarry LP bought a new stake in shares of CareDx in the 3rd quarter worth approximately $27,000. Harvest Fund Management Co. Ltd bought a new stake in CareDx during the 3rd quarter valued at $52,000. KBC Group NV bought a new stake in CareDx during the 3rd quarter valued at $99,000. nVerses Capital LLC raised its holdings in CareDx by 175.0% during the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company's stock valued at $103,000 after acquiring an additional 2,100 shares during the period. Finally, Quest Partners LLC grew its position in shares of CareDx by 37.8% during the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company's stock valued at $175,000 after purchasing an additional 1,540 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently commented on CDNA. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and reduced their price target for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. The Goldman Sachs Group boosted their price target on shares of CareDx from $26.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, October 16th. BTIG Research reduced their price target on shares of CareDx from $40.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, November 5th. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research report on Thursday, October 17th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $26.00 target price on shares of CareDx in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $28.33.

CareDx Price Performance

NASDAQ CDNA traded down $0.29 during trading on Friday, hitting $22.41. 706,432 shares of the company's stock traded hands, compared to its average volume of 786,407. The stock has a fifty day moving average of $22.80 and a two-hundred day moving average of $25.14. CareDx, Inc has a 12-month low of $7.42 and a 12-month high of $34.84. The firm has a market cap of $1.20 billion, a P/E ratio of -8.30 and a beta of 1.87.

Insider Buying and Selling at CareDx

In other CareDx news, Director Peter Maag sold 5,000 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the director now directly owns 330,024 shares in the company, valued at $8,250,600. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 4.90% of the company's stock.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.